Home/Pipeline/RIG-301 CFTR

RIG-301 CFTR

Cystic Fibrosis

Pre-clinicalActive

Key Facts

Indication

Cystic Fibrosis

Phase

Pre-clinical

Status

Active

Company

RIGImmune

About RIGImmune

RIGImmune is a private, preclinical-stage biotech founded in 2020 by Yale professors Anna Marie Pyle and Akiko Iwasaki. The company has built an integrated platform combining Stem Loop RNA (SLR) therapeutics, which selectively activate the RIG-I pathway, with the NEED™ (Nano-Emulsion Enhanced Delivery) platform for direct, non-LNP inhalation delivery. Its pipeline targets high-unmet-need respiratory conditions like asthma and cystic fibrosis, positioning it to address a significant market opportunity if its localized delivery approach proves successful in the clinic.

View full company profile

Therapeutic Areas

Asthma Cystic Fibrosis Respiratory Diseases

Other Cystic Fibrosis Drugs

Drug	Company	Phase	Status
CB-280	Calithera Biosciences	Preclinical/Phase 1	Discontinued
Ensifentrine	Verona Pharma	Phase 2	Under MSD
ALTA Drug Series	Alteron Therapeutics	Preclinical	Research
ColiFin®	Spexis	Marketed (EU)	Active
Cystic fibrosis (CRISPR)	GeneToBe	Discovery	Active
Cystic fibrosis (undisclosed)	GeneToBe	Early Discovery	Active
SM001 (alidornase/Tigerase)	SarcoMed USA	Research	Active
Targeted Lung Delivery	Nanite	Pre-clinical	Active
CFTR 100+ Panel	Agena Bioscience	Commercial	Active
CBN-101	Carbon Biosciences	Preclinical	Active
RESP® Biosensor Evaluation (with Rutgers Health)	Strados Labs	Research Study	Active
KIT2014	Kither Biotech	Phase 2	Active